학술논문
Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients.
Document Type
Academic Journal
Author
Cohen E; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Lheure C; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Ingen-Housz-Oro S; Department of Dermatology, APHP, Mondor Hospital, Paris, France, EpiDermE, University Paris Est Créteil, Créteil, France.; Hotz C; Department of Dermatology, APHP, Mondor Hospital, Paris, France.; Bettuzzi T; Department of Dermatology, APHP, Mondor Hospital, Paris, France.; Chasset F; Department of Dermatology, APHP, Tenon Hospital, Paris, France.; Descamps V; Department of Dermatology, APHP, Bichat Hospital, Paris, France.; Deschamps L; Department of Pathology, APHP, Bichat Hospital, Paris, France.; Mahevas M; Department of Internal Medicine, APHP, Mondor Hospital, Paris, France.; Terrier B; Department of Internal Medicine, APHP, Cochin Hospital, Paris, France.; Sohier P; Department of Pathology, APHP, Cochin Hospital, Paris, France.; Guegan S; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Kramkimel N; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Darbord D; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Chanal J; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Oulès B; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Aractingi S; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Seta V; Department of Dermatology, APHP, Cochin Hospital, Paris, France.; Dupin N; Department of Dermatology, APHP, Cochin Hospital, Paris, France.
Source
Publisher: John Libbey Eurotext Country of Publication: France NLM ID: 9206420 Publication Model: Print Cited Medium: Internet ISSN: 1952-4013 (Electronic) Linking ISSN: 11671122 NLM ISO Abbreviation: Eur J Dermatol Subsets: MEDLINE
Subject
Language
English
Abstract
Sarcoidosis is a systemic disease that affects the skin in about 25% of patients. The treatment of cutaneous sarcoidosis is guided by the extent of lesions, associated symptoms and organ involvement. To evaluate rates of response to various potential first-line treatments for cutaneous sarcoidosis during the year following treatment initiation. This retrospective multicentre study included 120 patients with cutaneous sarcoidosis. Treatment response was assessed retrospectively from the patients' medical records. Univariate logistic regression analysis, with an estimation of unadjusted odds ratios (OR) and their 95% CI ,was performed to identify factors associated with complete cutaneous remission (CR), followed by multivariate logistic regression analysis. At one year, 43 of the 120 (36%) included patients had CR. The best response rates were obtained with oral corticosteroids (12/21, 57%), followed by a combination of hydroxychloroquine and topical steroids (6/13, 46%). In multivariate analysis, lupus pernio was the only predictor of a poor cutaneous response. We suggest the use of a combination of hydroxychloroquine and topical steroids as an optimal first-line treatment for cutaneous sarcoidosis, given the known adverse effects of systemic corticosteroids.